Queen Elizabeth Hospital

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

Retrieved on: 
Wednesday, February 7, 2024

February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.

Key Points: 
  • February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.
  • In 2022, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This study is exploring the potential of glenzocimab in reducing the type of blood clotting responsible for heart damage during heart attacks.
  • Birmingham Health Partners is a strategic alliance between five organisations who collaborate to bring healthcare innovations through to clinical application:

The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

Retrieved on: 
Thursday, September 7, 2023

September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.

Key Points: 
  • September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.
  • In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This new clinical trial is based on a long-standing collaboration between Acticor Biotech and the University of Birmingham.
  • We are very pleased to receive regulatory approval to launch the LIBERATE clinical trial to investigate whether glenzocimab can reduce the type of blood clotting that causes heart damage during heart attacks.

Merit Medical’s WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

Retrieved on: 
Thursday, August 3, 2023

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study.

Key Points: 
  • SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study.
  • Creation and maintenance of an arteriovenous fistula or graft (AVF/AVG) to achieve long-term vascular access (access to blood vessels) is required for patients undergoing hemodialysis.
  • Merit intends to collect safety and efficacy outcomes throughout the study follow-up period.
  • Merit intends to follow patients enrolled in the WAVE study for 24 months following completion of enrollment.

JenaValve Announces First Trilogy Heart Valve Systems Implanted in Asia

Retrieved on: 
Thursday, May 18, 2023

IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia.

Key Points: 
  • IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia.
  • “The Trilogy Heart Valve System is a highly innovative treatment option licensed for both severe aortic regurgitation (AR) and severe aortic stenosis (AS) patients in Asia.
  • These cases mark a major milestone for the clinical use of Trilogy in Asia,” said John Kilcoyne, JenaValve Chief Executive Officer.
  • Together, JenaValve and Peijia Medical are committed to benefiting patients across Asia.

Microbix Presenting Results of Collaboration with Health PEI

Retrieved on: 
Monday, February 6, 2023

Microbix’s Quality Assessment Products (“QAPs™”) supporting test and test-workflow accuracy enabled it to assist Health PEI in verifying functionality and implementing use of the Becton Dickinson (“BD”) Onclarity™ HPV assay.

Key Points: 
  • Microbix’s Quality Assessment Products (“QAPs™”) supporting test and test-workflow accuracy enabled it to assist Health PEI in verifying functionality and implementing use of the Becton Dickinson (“BD”) Onclarity™ HPV assay.
  • Microbix HPV QAPs are available for sale in Canada, Australia, Europe, the United States, and other jurisdictions under its “REDx™ Controls” (IVD) or “PROCEEDx™” (RUO) brand names.
  • Diagnostic tests to detect infection with high-risk HPV provide important preventative health information and require validated, regulated, and third-party test-controls to help ensure their accuracy.
  • Microbix believes high-risk HPV infections and resulting cancers have gone undiagnosed and is pleased to help enable new MDx screening programs.

BiomeBank Continues Growth Trajectory With Over $10M Capital Raise

Retrieved on: 
Friday, December 9, 2022

BiomeBank today announced the successful capital raise of $10 million following the biotechnology companys world first regulatory approval of its donor derived microbiome drug product.

Key Points: 
  • BiomeBank today announced the successful capital raise of $10 million following the biotechnology companys world first regulatory approval of its donor derived microbiome drug product.
  • This includes BB265, its cultured therapy for ulcerative colitis to allow BiomeBank to conduct its first human clinical trial.
  • Investors that participated in the capital raise include Ellerston Capital and the South Australian Venture Capital Fund, managed by Artesian Venture Partners.
  • The Hospital Research Foundation, who provided founding seed capital and additional support to the company since 2018 committed further capital to this investment round.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Retrieved on: 
Monday, November 7, 2022

Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.
  • This designation for our biologic CAR T-cell therapy engager ALETA-001 marks an important step in addressing the high unmet need for patients who relapse or progress following CD19-targeted CAR T-cell therapy for blood cancers, such as lymphoma and leukemia, stated Paul Rennert, Co-Founder, Acting Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.
  • ALETA-001 is an off-the-shelf preclinical biologic program developed to treat and prevent cell therapy relapse of existing CD19-targeted CAR T-cell therapies, termed CAR19 T cells.
  • Aleta Biotherapeutics is an immune-oncology company with a portfolio and platform of novel off-the-shelf biologic CAR T engagers (CTEs) that work in synergy with cell therapies to improve outcomes for patients.

RCSI Bahrain Alumni Community on the rise in UK

Retrieved on: 
Tuesday, October 4, 2022

With the opportunity to connect with alumni, Professor Sameer Otoom, President of RCSI Bahrain led a feedback session and discussed new ideas and initiatives with the alumni.

Key Points: 
  • With the opportunity to connect with alumni, Professor Sameer Otoom, President of RCSI Bahrain led a feedback session and discussed new ideas and initiatives with the alumni.
  • Since 2010, RCSI Bahrain has 282 alumni from more than 30 nationalities currently working in the UK, making the UK the most prominent destination for our alumni community after Bahrain.Therefore, as part of RCSI Bahrain's ongoing commitment towards our alumni, weare pleased to collaborate with the Royal Society of Medicine to support first year graduates in their career development."
  • This eases the process of accessing internship and postgraduate training opportunities for all RCSI Bahrain medical graduates in the UK, regardless of their nationality.
  • The RCSI Bahrain alumni network now consists of over 2,700 practising professionals in over 30 countries.

RCSI Bahrain Alumni Community on the rise in UK

Retrieved on: 
Tuesday, October 4, 2022

With the opportunity to connect with alumni, Professor Sameer Otoom, President of RCSI Bahrain led a feedback session and discussed new ideas and initiatives with the alumni.

Key Points: 
  • With the opportunity to connect with alumni, Professor Sameer Otoom, President of RCSI Bahrain led a feedback session and discussed new ideas and initiatives with the alumni.
  • Since 2010, RCSI Bahrain has 282 alumni from more than 30 nationalities currently working in the UK, making the UK the most prominent destination for our alumni community after Bahrain.Therefore, as part of RCSI Bahrain's ongoing commitment towards our alumni, weare pleased to collaborate with the Royal Society of Medicine to support first year graduates in their career development."
  • This eases the process of accessing internship and postgraduate training opportunities for all RCSI Bahrain medical graduates in the UK, regardless of their nationality.
  • The RCSI Bahrain alumni network now consists of over 2,700 practising professionals in over 30 countries.